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Abstract: In this study, we aimed to develop a thrombus-targeting delivery system of   collagenase 
bound to a monoclonal antibody, and to investigate the thrombolysis of an immune-conjugate 
in vitro and in vivo as well as the targeting effect. We prepared the immunizing conjugation of 
collagenase by the 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI) method. In order 
to conjugate collagenase and a monoclonal antibody, bovine serum albumin was used as a 
linker, increasing the number of collagenase molecules carried and keeping collagenase and 
the monoclonal antibody active. In vitro thrombolysis experiments showed that collagenase 
had a strong dissolving effect on collagen-embolus within 24 hours. We established a rabbit 
pulmonary embolism model to investigate the thrombolysis effect of collagenase and colla-
genase immunizing conjugation in vivo. Our results revealed a significant difference between 
collagenase and collagenase immunizing conjugation (P , 0.05). We also established a rabbit 
ear edge vein model to investigate the active target of collagenase immunizing conjugation. 
We found that collagenase immunizing conjugation had active targets, and had a strong abil-
ity to dissolve organized thrombi. In conclusion, the thrombus-targeting delivery system of 
  collagenase we developed has active targeting effects on thrombi.
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Introduction
Several agents are used to treat thromboembolic diseases. These agents can be 
  classified by their mechanism of action as follows.1–4 1) Anticoagulants (such as 
heparin and coumarin), which prevent the formation of thrombi and the development 
of thrombi by interfering with the process of blood coagulation. 2) Antiplatelet drugs 
(such as aspirin, dipyridamole and hirudin), which inhibit the adhesion, aggregation 
and release of platelets to prevent the formation of thrombi. These drugs are usually 
used in the treatment of cardiovascular diseases, cerebral ischemia and peripheral 
embolism. 3) Thrombolytic agents (such as streptokinase, urokinase and tissue-type 
plasminogen activator), which convert zymogen plasminogen into an active form of 
serine proteinase plasmin, and then initiate or accelerate the process of fibrinolysis 
and degrade the fibrin network of thrombi and blood clots.
However, when apoplexy occurs and is not treated in time, the thrombus would 
become organized over time. Organization of the thrombus by cells of the surround-
ing vessel cells was demonstrated by Virchow and later confirmed by Aschoff.5,6 
The matrix surrounding these cells was shown to be rich in collagen fibers.7 The 
collagen of an organized thrombus then interferes with the effect of thrombolysis. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
974
Lu et al
  Streptokinase and fibrinolysin have been shown to have no 
effect on the solubility of native and denatured collagen, 
which could be degraded by collagenase.8 Collagenase is 
a type of proteolytic enzyme that can hydrolyze collagen 
at appropriate pH and temperature. Therefore, using col-
lagenase would be a good strategy to dissolve an organized 
thrombus. Collagenase may achieve active targeting by 
binding to a monoclonal antibody or antibody fragment, 
such as third-generation thrombolytic agents which have 
a special affinity to organized thrombus. The immunizing 
conjugation of collagenase can be targeted to a thrombus 
and dissolve the thrombus effectively, and it also can reduce 
the side-effects of collagenase.
A drug and a monoclonal antibody can be crosslinked 
by chemical reactions. Then, the biological activity of the 
drug and antibody of conjugation should be sustained, and 
the toxicity of conjugation does not increase. In the past few 
years, the method of crosslinking a drug and a monoclonal 
antibody with a carrier has been widely used. An intermedi-
ate is first obtained from a drug combined with some com-
pounds or polymers or vehicle, then the intermediate binds 
with a monoclonal antibody to form an immune-conjugate. 
The usual crosslinking reactions include direct oxidation,9 
the dextran T-40 method,10 the activated ester method,11 the 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI) 
method,12,13 the cyanogens bromide method,14 the mixed 
anhydride method,15 and so on. A reasonable crosslinking 
method should meet the following requirements: high yield 
of cured product, homogeneous composition, sustained activ-
ity, simple operation, good reproducibility, easy separation 
and purification.
Materials and methods
Materials
Collagenase was purchased from the Shanghai Institute 
of Pharmaceutical Industry (Shanghai, China). Collagen, 
EDCI and anti-collagen monoclonal antibody (McAb) 
were purchased from Sigma (USA). Ninhydrin was pur-
chased from Shanghai SSS Reagent (China). Bovine serum 
albumin (BSA) was purchased from Shanghai Bio-Life 
Science and Technology Co., Ltd (China). Fluorescein 
isothiocyanate (FITC) was purchased from Amresco 
(USA). Polyethylene glycol (PEG) 6000 was purchased 
from Bazhou Chemical Plant Factory of Tianjin Crystal 
Clock Factory (China).
Rabbits, of body weight of 2.0 to 2.5 kg, were pro-
vided by the West China Laboratory Animal Center of 
Sichuan University. All experiments were approved by the 
Institutional Animal Care and Use Committee of Sichuan 
University.
Methods
Activity assay methods
collagenase assay
Ninhydrin-based assay:16 0.5 mL of solution was mixed with 
0.5 mL of phosphate-buffered saline (PBS) (0.05 mol/L, 
pH 7.4) in test tubes. Then 0.5 mL of collagenase of dif-
ferent concentrations and 0.5 mL of CaCl2 (0.05 mol/L) 
were separately added and the tubes were shaken evenly. 
The above mixtures were incubated at 37°C for 30 minutes, 
mixed with 0.5 mL of freshly prepared ninhydrin reagent and 
heated for 20 minutes in a boiling water bath. After cool-
ing, the mixture was diluted with 1.5 mL of water to obtain 
appropriate concentrations for absorbance measurements, 
and then centrifuged for 5 minutes (8000 rpm). Absorbance 
was measured at 566 nm by a UV1000 Spectrophotometer 
(Shanghai, China).
stability of collagenase
Stability of collagenase solution: Collagenase solution was 
stored at 4°C and sampled at different time points. Then 
the activities of the samples were determined by ninhydrin-
based assay.
Thermal stability of collagenase solution: Collagenase 
solution was incubated at different temperatures and sampled 
at different time points. Then the activities of the samples 
were determined by ninhydrin-based assay.
selection of crosslink agent
Several crosslink agents (glutaraldehyde, succinimide, 
acetone, EDCI) were mixed with collagenase and the activity 
of the collagenase was determined.
McAb assay (enzyme-linked immunosorbent assay)
Enzyme-linked immunosorbent assay (ELISA) was per-
formed with washes in PBS pH 7.4 containing 0.05% 
Tween-20, 0.1% BSA, 2 × 10–3 EDTA (PBS-Tween-BSA-
EDTA) between each step. ELISA plates were coated by 
collagen diluted in 0.05 mol/L Tris-HCl buffer (pH 7.6, 
containing 0.15 mol/L NaCl). After overnight incubation 
at 4°C, plates were blocked for 20 hours at 4°C in PBS pH 
7.4 containing 0.1% BSA and 0.05% Tween-20, before 
adding the samples appropriately diluted in PBS-Tween-
BSA-EDTA. After overnight incubation at 4°C, monoclonal International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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  anti-collagen was detected by incubating at 37°C for 1 hour 
with a horseradish peroxidase-labeled goat polyclonal 
antibody (diluted in 1:1000 by PBS-Tween-BSA-EDTA). 
Then, the enzyme substrate ortho-phenylenediamine 
(1 mg/mL in citrate   buffer solution pH 4.5 adding 30% H2O2 
1µL/mL, prepared before reaction) was added to the plate 
and reacted exactly for 10 minutes at room temperature. 
Enzyme reaction was stopped by adding 2 mol/L sulfuric 
acid solution. Absorbance was measured at 490 nm on a 
microplate reader.
Preparation of collagenase-BsA-anti-
collagen monoclonal antibody  
(coll.-BsA-McAb) immune-conjugate
Coll.-BSA conjugate was prepared by the EDCI method.17–19 
Then the conjugate was separated from free collagenase and 
BSA by passing the mixture through a Sephadex G25 gel 
(Sigma, USA) exclusion chromatography (GEC) column 
with purified water as eluent and condensed by PEG 6000 
to 1.5 mL.
The purified and concentrated Coll.-BSA was mixed 
with 0.5 mL EDCI (1 mg/mL) and 50 µL anti-collagen 
monoclonal antibody solution, and then the mixture was 
churned in an ice-cold water bath for 30 minutes. Subse-
quently, the conjugate was separated from free collagenase 
and BSA by passing the mixture through a Sephadex G25 
GEC column with purified water as eluent and condensed 
by PEG 6000 to 1.5 mL.
Measuring the effect of coll.-BsA-McAb  
on thrombolysis in vitro
Preparation of collagen-coated thrombi
The collagen solution (4 mg/mL, dissolved with 0.05 mol/L 
acetic acid) neutralized by NaOH (0.5 mol/mL) was injected 
into an enclosed polyethylene plastic tube (length: 20 cm, 
internal diameter: 2.5 mm), and then the tube was incubated 
in a water bath at 37°C for 15 minutes. Fresh blood from 
rabbit ear vein was injected into the pre-heated tube with 
inner collagen coating, and the tube was incubated in a water 
bath at 37°C for 30 minutes. Finally, the collagen-coated 
thrombi was pushed out from the tube and cut into pieces 
2 cm long.
Determining thrombi weight
A series of collagen-coated thrombi were weighed, put into 
0.01 mol/L pH7.4 PBS (containing 0.9% NaCl), taken out, 
blotted dry on filter paper and weighed (Wn) at set time points. 
Then the thrombi were put into PBS again. This procedure 
was repeated 3 times.
Thrombolysis assay in vitro
The effect of Coll.-BSA-McAb immune-conjugate on 
thrombolysis in vitro was examined by a circulation system 
(Figure 1). Briefly, the channels were connected by poly-
ethylene plastic tubes (length: 70 cm, and internal diameter: 
2.5 mm) and glass tubes (length: 6 cm, and internal diameter: 
7.5 mm), and 2 terminals were sealed by rubber plugs. Three 
bottles of sample solution, which were prepared by PBS (pH 
7.40, 0.01 mol/L), were incubated in a water bath at 37°C. 
In order to simulate the circulation system, the driving force 
was provided by a peristaltic pump, and a constant flow rate 
was set at 2 mL/min.
The collagen emboli were taken out, blotted dry on filter 
papers and weighed (Wn) at set time points, and then put in 
the glass tubes. The thrombolysis rate in vitro was calculated 
according to the following formula: thrombolysis rate (%) = 
[(W0 - Wn)/W0] × 100%.
Measuring the effect of coll.-BsA-McAb 
immune-conjugate on thrombolysis in vivo
establishment of a pulmonary embolism  
model in rabbits
A catheter was inserted into an external jugular vein of an 
anesthetized animal, and then 2 pieces of weighed emboli 
(W0) (prepared as described above) were injected into the rab-
bit to generate a pulmonary embolism model. Subsequently, 
the catheter was ligatured, and the incision was sutured.
Water bath, 37°C
Control solution
Experiment solution
Clot
Porous
Peristaltic
Figure 1 An abridged general view of the apparatus for measuring the effect of 
coll.-BsA-McAb immune-conjugate on thrombolysis in vitro.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Thrombolysis assay in vivo
Five minutes after embolus injection, the rabbits were 
intravenously administered with 15 mL blank normal saline 
(NS) solution (blank control group), collagenase NS solu-
tion (the standard group) and immunoconjugate NS solution 
(the experimental group), respectively. The rabbits were 
sacrificed by carotid artery exsanguinating 24 hours after the 
operation, and the hearts and lungs were dissected. Then, the 
incompletely dissolved emboli were dried with filter paper 
and weighed (Wn). And the thrombolysis rate in vivo was 
calculated according to the following formula: thrombolysis 
rate (%) = [(W0 - Wn)/W0] × 100%.
Measuring the targeting effect  
of coll.-BsA-McAb immune-conjugate
establishment of an ear vein embolism  
model in rabbits
In 1856, Virchow proposed a classic view about the factors 
(such as abnormal changes of the blood vessel wall, constitu-
ents of blood and blood flow) that influence thrombosis devel-
opment.20 Injuring the blood vessel endothelium is a general 
method of thrombosis.21 Briefly, #8 syringe needles were 
processed as follows: the tips of the needles were blunted, and 
the edges of the needle tubes were roughened. The modified 
needles were pierced into ear vein of rabbit, and the blood 
vessel wall was repeatedly rubbed by the needle. Then the 
puncture point was compressed to staunch bleeding, and a 
marker was made at the embolism site.
coll.-BsA-McAb immune-conjugate labeled by FITc
The FITC solution dissolved in buffer bicarbonate (pH 
9.5) was added drop by drop into collagenase immunizing 
conjugation solution. The mixture was churned in an ice-
cold water bath for 2 hours (pH . 9). Then the mixture was 
purified by Sephadex G25 column (20 × 2.2 cm) with water 
as eluent. The first eluent section was collected, and the 
collagenase immunizing conjugation was labeled by FITC 
(FITC-  Coll.-BSA-McAb).
evaluation of the thrombotic targeting  
of conjugate in rabbits
After the ear vein embolism model was established, all 
rabbits were injected with 0.5 mL drug solution above a 
thrombotic blood vessel on day 7. Rabbits were intrave-
nously administered either with FITC-Coll.-BSA-McAb 
NS solution (4 mg collagense per kg body weight) or 
FITC-collagenase NS solution (4 mg collagense per kg 
body weight), respectively, and then 10 mL NS solution 
was administered for both groups. After 1 hour, a marked 
segment of ear was processed to obtain frozen sections of 
50 µm thickness. The sections were photographed with a 
Leica DMR fluorescence microscope.
Statistical analyses
Data were analyzed by using t-tests and one-way ANOVA 
(S-N-K comparison). Data are expressed as mean ± SD and 
differences considered significant when P , 0.05.
Results
Activity assay
collagenase assay
Assay study showed a linear increasing in the activities of 
collagenase with concentrations, with the regression equation 
of A = 5.195C - 0.1458 (r = 0.9976) during the concentra-
tions range of 0.04–0.20 mg/mL.
stability of collagenase
The results (Table 1) show that collagenase solution was 
stable for 2 hours at 4°C. Table 2 showed that collagenase 
solution was sensitive to heat. Collagenase activity was 
unchanged for 2 hours at 25°C, but dropped sharply at over 
50°C and became almost inactive after 2 hours.
selection of crosslink agent
Glutaraldehyde, succinimide and acetone clearly reduced 
collagenase activity. Because EDCI had the least influ-
ence on collagenase activity (Table 3), it was chosen as the 
crosslink agent.
Preparation of immunoconjugate
The activities of Coll., McAb in Coll.-McAb and Coll.- 
BSA-McAb were measure respectively after preparation. 
Table 4 shows that the activities of Coll. and McAb were both 
higher in immune-conjugate with BSA as linker than those 
in Coll.-McAb; and Figures 2 and 3 show that the activities 
Table 1 The stability of collagenase solution (n = 3, X ± sD)
Time (h) 0 0.5 1 2 4 6
A566 nm 0.499 ± 0.022 0.47 ± 0.023 0.504 ± 0.019 0.500 ± 0.018 0.431 ± 0.021 0.376 ± 0.018International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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and the control group (Coll.) (P . 0.05), indicating that the pro-
cess of crosslinking McAb did not affect collagenase activity.
The effect of coll.-BsA-McAb immune-
conjugate on thrombolysis in vivo
establishment of a pulmonary embolism  
model in rabbits
We did not find emboli in cardiac artery, while the emboli were 
partially dissolved in the small pulmonary artery branches. 
This observation confirmed that the emboli injected reached 
the pulmonary arterial vasculature and the pulmonary embo-
lism model was successfully established (Figure 7).
Thrombolysis assay in vivo
Table 7 shows that Coll.-BSA-McAb immune-conjugate 
and Coll. could both increase the thrombolysis rate in vivo. 
There was a significant difference (P , 0.05) between 
Coll.-BSA-McAb immune-conjugate and Coll., suggest-
ing that Coll.-BSA-McAb immune-conjugate has a better 
thrombolysis effect than Coll.
The targeting effect of Coll.-BSA-
McAb immune-conjugate
establishment of an ear vein embolism 
model in rabbits
Figure 8 shows that that a thrombus was formed, and thus 
establishing the ear vein embolism model.
FITc-coll.-BsA-McAb
We observed the immune-conjugate labeled with a fluorescence 
microscope after purification. The bright green dot is the colla-
genase immunizing conjugation labeled by FITC (Figure 9).
Targeting effect
The thrombus was covered with fluorescence in the image 
of the experimental group (Figure 11), indicating that colla-
genase immunizing conjugation labeled by FITC aggregated 
at the thrombus site. In contrast, there was no fluorescence 
in the image of the control group (Figure 10). These results 
indicate that collagenase immunizing conjugation has active 
targeting effects in vivo.
Table  2  Absorption  of  A566  nm  of  collagenase  at  different 
temperatures (n = 3, X ± sD)
Time 
(min)
Temperature (°C)
25 37 50 60
0 0.514 ± 
30 0.529 ± 0.002 1.356 ± 0.001 0.753 ± 0.001 0.894 ± 0.001
60 0.569 ± 0.002 0.837 ± 0.001 0.764 ± 0.001 0.401 ± 0.002
90 0.589 ± 0.001 0.726 ± 0.003 0.298 ± 0.001 0.004 ± 0.001
120 0.579 ± 0.001 0.648 ± 0.003 – –
Table 3 Influence of different cross-linking agents on collagenase activity (n = 3)
Agent H2O Glutaraldehyde Succinimide Acetone EDCI
concentration 0.5 mL 1.25% 1.25% 0.5 mL 1.25%
A566 0.731 ± 0.018 0.098 ± 0.003 0.143 ± 0.006 0.197 ± 0.010 0.291 ± 0.016
of Coll. and McAb in Coll.-BSA-McAb were higher than 
in Coll.-McAb.
The effect of Coll.-BSA-McAb  
on thrombolysis in vitro
Preparation of thrombi coating collagen
A collagen embolus of good form and strength was obtain 
according to the method described in Preparation of 
collagen-coated thrombi (Figure 4). A collagen embolus 
was confirmed by the fluorescent layer coating the collagen 
embolus (Figure 5).
Determining the weight of thrombi
Table 5 shows the weights of these thrombi, suggesting that 
the water soaking process would cause larger errors if the 
thrombus is too small, and smaller errors if the thrombus has 
a certain weight. The results indicate that weighing the throm-
bus can be used to evaluate the effect of Coll.-BSA-McAb 
on thrombolysis in vitro. Heavy thrombi should be chosen 
in order to minimize the error.
Thrombolysis assay in vitro
Figure 1 shows the thrombolytic experiment in vitro as 
described above. Table 6 shows that the thrombus would dis-
solve by itself in PBS. Figure 6 shows the collagen embolus 
thrombolysis rate at different time points after the deduction 
of the blank control.
Table 6 and Figure 6 indicate that Coll.-BSA-McAb 
immune-conjugate and Coll. could increase the thrombolysis 
rate in vitro. The thrombolysis effects did not differ signifi-
cantly between the experimental group (Coll.-BSA-McAb) International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Discussion
The EDCI method is a generally mild reaction at pH 5.0–9.0 
and at 4°C or room temperature.22 The reaction mechanism is 
as follows: an intermediate is produced by the reaction of the 
protein carboxyl (-COOH) with EDCI, and then the interme-
diate reacts with the primary amino acid to form a coupled 
product.22 EDCI would not be retained in the conjugate, but 
transformed into a water-soluble urea derivative with low 
cytotoxicity. So this method avoids depolymerization and 
release of the residual toxic substance. Several common 
crosslinkers, such as glutaralaldehyde, succinimide, acetone 
and EDCI, have been investigated in our previous studies. 
Among these, EDCI has the least effect on the activity of 
collagenase.
Currently, drug-McAb is in short supply23 for several 
reasons. 1) Drug-McAb conjugate can be associated with any 
other antigen in circulation before it reaches the target site; 
2) the chemical bond between drug and monoclonal antibody 
is destroyed by oxidoreductase and protease in circulation 
before it reaches the target site; 3) the quantity of drug 
crosslinking with monoclonal antibody is limited. When the 
ratio of drug molecules and monoclonal antibody molecules 
reaches 10:1, it would result in inactivation of monoclonal 
antibody. If a carrier with many drug and monoclonal anti-
body binding sites was a linker to conjugate drug and anti-
body to form drug-linker-McAb conjugation, it might carry 
more drug molecules and remain active at antigen-binding 
sites. In this study, our results showed that the activities of 
collagenase and McAb were higher in immune-conjugate 
with BSA as linker than those in Coll.-McAb. This result 
suggests that BSA as linker to prepare Coll.-BSA-McAb 
immune-conjugate enables the conjugation to carry more 
collagenase molecules.
Figure 5 collagen embolus labeled by FITc.
Table 4 Activities of coll. and McAb in coll.-McAb and coll.-
BsA-McAb (n = 3, mean ± sD)
Sample Coll. Coll.-McAb Coll.-BSA-McAb
collagenase A566 nm 0.695 ± 0.038 0.332 ± 0.012 0.473 ± 0.010
McAb A490 nm – 0.136 ± 0.005 0.263 ± 0.006
−0.2
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Figure 2 The activity of collagenase in an eluent series.
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Figure 3 The activity of collagenase in an eluent series.
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The volume of reaction solution generally increases about 
10-fold after passing a GEC column. So the effluent liquid 
should be enriched to guarantee enough concentration of 
antibody during the crosslinking. Many methods for enrich-
ing protein solution are available,24–32 such as lyophilization, 
vacuum drying, using glucosan to absorb water, the PEG 
concentration method, ultra-filtration member separation tech-
nology, foam fractionation and so on. Here we chose the PEG 
concentration method to enrich the effluent liquid, since the 
rate of water absorption was very fast. During the concentra-
tion procedure, the solution volume in the dialysis bag should 
be carefully monitored to avoid overdehydration because the 
hydrated PEG also has a strong water absorption function.
In our study, a series of thrombi coating collagens were 
prepared by soaking, blotting dry on filter papers and weigh-
ing 3 times. Our results showed that there would be larger 
errors if the thrombus is too small; and smaller errors would 
be obtained if the thrombus has a certain weight. Therefore, 
larger thrombi should be used.
Several thrombus models have been reported,33–36 such 
as rabbit ear vein embolism model, jugular artery/vein 
thrombosis model, femoral artery/vein thrombosis model, 
pulmonary embolism model and so on. In our study, we 
chose the rabbit pulmonary embolism model and the rabbit 
ear vein embolism model. In the first model, the partially 
dissolved emboli were found in the small pulmonary artery 
branches but not in cardiac. We inferred the route of emboli 
in blood vessels from the investigation as: external jugular 
vein–jugular vein–superior vena cava–right atrium–right 
ventricle–pulmonary artery–pulmonary artery branch. The 
thrombolysis assay in vivo showed that the thrombolysis 
rate of the Coll.-BSA-McAb/Coll. group was significantly 
higher than that of the PBS group, and the thrombolysis 
rate of Coll.-BSA-McAb group was significantly higher 
than that of Coll. group, which might be due to a sterically 
hindered protective effect and targeting effect. Besides car-
rying more collagenase molecules, BSA with a larger vol-
ume could protect collagenase from degradation by enzyme 
in vivo for steric hindrance of group in BSA. In addition, the 
Coll.-  BSA-McAb could aggregate around a thrombus with 
the help of a monoclonal antibody, which could increase the 
thrombolysis rate. In contrast, some collagenase molecules 
without sterically hindered protective activities from vehicle 
may be degraded by enzyme and deactivated before they 
arrive in targeted thrombi. Compared with Coll.-BSA-McAb, 
more free collagenase would be distributed to other tissues for 
less targeting effect, thereby reducing the effective quantity 
of collagenase. We speculated on the targeting effect of Coll.-
BSA-McAb from the statistical difference in thrombolysis 
rates between Coll.-BSA-McAb and collagenase.
The preparation method of rabbit ear vein embolism 
model is suitable for studying targeting effect because it 
is simple and straightforward. Until day 7 after the blood 
vessel was injured, thrombus organization occurred, 
indicating that the establishment of the ear vein embo-
lism model was successful and could be used for further 
experiments. In our study, the injection site was upstream 
of the embolic site, so the drug solution flowed over the 
thrombus surface. Then liquor NS solution was slowly 
injected to remove nonspecific binding. The aggregat-
ing of fluorescence at the thrombus site was due to the 
combination reaction of antigen (collagen) and antibody 
(anti-collagen monoclonal antibody), which was part of 
Coll.-BSA-McAb labeled by FITC.
Table 5 Variance in weight of collagen embolus (n = 3, mean ± sD)
No. Weight (mg)
1 2 3 4 5 6
1 64.7 52.1 49.6 32.0 13.3 6.4
2 59.8 50.8 46.1 26.2 10.2 5.7
3 57.2 47.2 42.7 24.9 8.9 3.9
Average 60.6 ± 3.81 50.0 ± 2.54 46.1 ± 3.45 27.7 ± 3.78 10.8 ± 2.26 5.3 ± 1.29
Table 6 Average thrombolysis rate (%) of collagen embolus (n = 3, mean ± sD)
Time (h) 2 4 8 18 20 24
coll.-BsA-McAb 11.09 ± 0.49 22.34 ± 3.09 33.91 ± 4.16 67.60 ± 2.10 100.00 ± 0 100.00 ± 0
coll. 15.74 ± 4.39 26.38 ± 6.73 38.92 ± 3.36 65.88 ± 2.39 100.00 ± 0 100.00 ± 0
PBs   2.41 ± 1.55   9.28 ± 0.88 19.63 ± 6.60 28.70 ± 8.56   40.00 ± 8.99   50.93 ± 6.93
Notes: Rates of thrombolysis caused by PBS and Coll.-BSA-McAb/Coll. differed signficantly (P , 0.05), but rates of thrombolysis caused by coll.-BsA-McAb and coll. did 
not (P . 0.05).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Summary
Coll.-BSA-McAb, an immune-conjugate prepared by the EDCI 
method, was developed to carry more drug molecules to target 
thrombi accompanied by a less systematic side effect. In vitro 
thrombolysis study indicated that collagenase immunizing 
conjugation can dissolve organized thrombus well, and proved 
that the process of crosslinking McAb would not influence the 
activities of collagenase and monoclonal antibody. As a result, 
Coll.-BSA-McAb was shown to have a better thrombolysis 
effect than collagenase in vivo. Coll.-BSA-McAb can be ori-
ented specifically to the thrombus via a monoclonal antibody, 
which was demonstrated by the better thrombolysis effect of 
Coll.-BSA-McAb than collagenase in vivo and aggregation of 
fluorescence at the thrombus site. In summary, this study has 
shown a new approach for developing a monoclonal antibody 
conjugated collagenase for thrombus targeting.
Figure 10 Distribution of collagenase immunizing conjugation labeled by FITc.
Table 7 In vivo thrombolysis rates (%) of rabbit lung thrombosis 
model (n = 5, mean ± sD)
Group Coll.-BSA-McAb Coll. PBS
Average  
thrombolysis  
rate (%)
78.14 ± 6.02 65.32 ± 9.92 49.24 ± 10.02
Notes: rate of thrombolysis caused by PBs and coll.-BsA-McAb/coll. differed 
significantly  (P  ,  0.05).  Although  coll.-BsA-McAb  and  coll.  showed  similar 
thrombolytic  potencies  in  rabbit  lung  thrombosis  model,  rates  of  thrombolysis 
caused by Coll.-BSA-McAb and Coll. differed significantly.
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Figure 6 collagen embolus thrombolysis rate after deduction of the blank control.
Figure 7 Isolated lung and clots in pulmonary artery.
Figure 8 Thrombosis formed in rabbit ear vein.
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